1. Home
  2. KBDC vs CGEM Comparison

KBDC vs CGEM Comparison

Compare KBDC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

N/A

Current Price

$13.66

Market Cap

941.8M

Sector

N/A

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$16.19

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KBDC
CGEM
Founded
2021
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.8M
780.4M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KBDC
CGEM
Price
$13.66
$16.19
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$15.50
$29.89
AVG Volume (30 Days)
424.4K
780.3K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
13.92%
N/A
EPS Growth
N/A
N/A
EPS
1.67
N/A
Revenue
N/A
N/A
Revenue This Year
$193.84
N/A
Revenue Next Year
$9.00
N/A
P/E Ratio
$8.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.06
$5.68
52 Week High
$16.98
$16.74

Technical Indicators

Market Signals
Indicator
KBDC
CGEM
Relative Strength Index (RSI) 42.36 69.79
Support Level $13.54 $6.65
Resistance Level $15.25 $16.74
Average True Range (ATR) 0.35 1.04
MACD 0.02 0.15
Stochastic Oscillator 50.60 90.36

Price Performance

Historical Comparison
KBDC
CGEM

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: